Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity: A Phase I Trial

OBJECTIVES: This study sought to evaluate the safety of continuing trastuzumab in patients with human epidermal growth factor receptor–positive breast cancer who developed mild cardiotoxicity. BACKGROUND: Cardiotoxicity is the most common dose-limiting toxicity associated with trastuzumab. Current s...

Descripción completa

Detalles Bibliográficos
Autores principales: Leong, Darryl P., Cosman, Tammy, Alhussein, Muhammad M., Kumar Tyagi, Nidhi, Karampatos, Sarah, Barron, Carly C., Wright, Douglas, Tandon, Vikas, Magloire, Patrick, Joseph, Philip, Conen, David, Devereaux, P.J., Ellis, Peter M., Mukherjee, Som D., Dhesy-Thind, Sukhbinder
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352338/
https://www.ncbi.nlm.nih.gov/pubmed/34396157
http://dx.doi.org/10.1016/j.jaccao.2019.06.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352338/
https://www.ncbi.nlm.nih.gov/pubmed/34396157
http://dx.doi.org/10.1016/j.jaccao.2019.06.004

Ejemplares similares